Next Article in Journal
Sex Differences in Taxane Toxicities
Next Article in Special Issue
Artificial Intelligence Analysis Using MRI and PET Imaging in Gliomas: A Narrative Review
Previous Article in Journal
Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Advances in the In Vivo Quantitative and Qualitative Imaging Characterization of Gliomas

by
Pierpaolo Alongi
1,* and
Ignazio Gaspare Vetrano
2
1
Nuclear Medicine Unit, A.R.N.A.S. Ospedale Civico Di Cristina Benfratelli, 90127 Palermo, Italy
2
Department of Neurosurgery, Neuro-Oncological Surgery Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(14), 3324; https://doi.org/10.3390/cancers14143324
Submission received: 6 June 2022 / Revised: 13 June 2022 / Accepted: 2 July 2022 / Published: 8 July 2022
Gliomas are the most common and aggressive intra-axial primary tumours of the central nervous system (CNS), arising from glial cells. The poor prognosis of these tumours partly results from a lack of significant advances in early diagnosis and treatments prolonging life [1].
Most of the available local treatment options, including radiotherapy and neurosurgery, heavily depend on precise knowledge of the type, location, and extent of the tumour. Visual assessments of medical imaging represent a unique possibility for the detection, characterization, and monitoring of diseases. Qualitative evaluations still represent the modality for intraoperative assessments using ultrasound (ioUS) and/or optical coherence tomography (OCT) to identify lesions and potential residue, analyse the vascularization pattern, and characterise the nature of the mass. Technological advances in both structural and functional imaging (MR and PET imaging) also enables defining several images features, through multiparametric and quantitative evaluations of gliomas [2,3].
In the field of quantitative imaging, the main issues regard the acquisition/reconstruction parameters, tissue segmentation, feature extraction/selection, and the appropriate statistical analysis of data [4].
Radiomics analysis, considered to be the most advanced development inimage quantification, may provide valuable diagnostic, prognostic, and predictive information of tumours. However, its role in gliomas is still undefined. Numerous studies have demonstrated the correlation between the heterogeneity of the tissues and the radiomics features, which can obtain relevant information not conventionally assessable in medical imaging [5,6]. Future perspective studies will be necessary to discover new possible correlations among clinical, genetic/molecular, and image features of gliomas.
There is still a need to validate the advanced use of MR and PET techniques, as the diagnostic methods increasingly utilized in clinical and research settings [7,8,9,10]. Potential advantages are still to be confirmed on the evaluation of gliomas, to define the progression of disease and for monitoring high-grade gliomas [11,12].
Diagnoses, disease extensions, vascularization patterns, differential diagnoses between low-grade and high-grade gliomas, and definitions of disease status after treatment remains the main issues of medical imaging in gliomas. This Special Issue will focus on developing in vivo quantitative and qualitative imaging (CT, OCT, MRI, PET/CT, and PET/MR), also considering the novel application of radiomics-based analysis to improve the current role of imaging in the management of gliomas.
We invite authors to submit contributions of novel findings or reviews that comprehensively highlight the latest discoveries in the field.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro Oncol. 2021, 23, 1231–1251. [Google Scholar] [CrossRef] [PubMed]
  2. Prada, F.; Ciocca, R.; Corradino, N.; Gionso, M.; Raspagliesi, L.; Vetrano, I.G.; Doniselli, F.; Del Bene, M.; DiMeco, F. Multiparametric Intraoperative Ultrasound in Oncological Neurosurgery: A Pictorial Essay. Front. Neurosci. 2022, 16, 881661. [Google Scholar] [CrossRef] [PubMed]
  3. Yashin, K.; Bonsanto, M.M.; Achkasova, K.; Zolotova, A.; Wael, A.M.; Kiseleva, E.; Moiseev, A.; Medyanik, I.; Kravets, L.; Huber, R.; et al. OCT-Guided Surgery for Gliomas: Current Concept and Future Perspectives. Diagnostics 2022, 12, 335. [Google Scholar] [CrossRef]
  4. Zhang, Z.; He, K.; Wang, Z.; Zhang, Y.; Wu, D.; Zeng, L.; Zeng, J.; Ye, Y.; Gu, T.; Xiao, X. Multiparametric MRI Radiomics for the Early Prediction of Response to Chemoradiotherapy in Patients With Postoperative Residual Gliomas: An Initial Study. Front. Oncol. 2021, 11, 779202. [Google Scholar] [CrossRef] [PubMed]
  5. Garcia-Ruiz, A.; Naval-Baudin, P.; Ligero, M.; Pons-Escoda, A.; Bruna, J.; Plans, G.; Calvo, N.; Cos, M.; Majós, C.; Perez-Lopez, R. Precise Enhancement Quantification in Post-Operative MRI as an Indicator of Residual Tumor Impact Is Associated with Survival in Patients with Glioblastoma. Sci. Rep. 2021, 11, 695. [Google Scholar] [CrossRef] [PubMed]
  6. Liu, C.; Li, Y.; Xia, X.; Wang, J.; Hu, C. Application of Radiomics Feature Captured from MRI for Prediction of Recurrence for Glioma Patients. J. Cancer 2022, 13, 965–974. [Google Scholar] [CrossRef]
  7. Henriksen, O.M.; del Mar Álvarez-Torres, M.; Figueiredo, P.; Hangel, G.; Keil, V.C.; Nechifor, R.E.; Riemer, F.; Schmainda, K.M.; Warnert, E.A.H.; Wiegers, E.C.; et al. High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques. Front. Oncol. 2022, 12, 810263. [Google Scholar] [CrossRef]
  8. Booth, T.C.; Larkin, T.J.; Yuan, Y.; Kettunen, M.I.; Dawson, S.N.; Scoffings, D.; Canuto, H.C.; Vowler, S.L.; Kirschenlohr, H.; Hobson, M.P.; et al. Analysis of Heterogeneity in T2-Weighted MR Images Can Differentiate Pseudoprogression from Progression in Glioblastoma. PLoS ONE 2017, 12, e0176528. [Google Scholar] [CrossRef] [PubMed]
  9. Cistaro, A.; Albano, D.; Alongi, P.; Laudicella, R.; Pizzuto, D.A.; Formica, G.; Romagnolo, C.; Stracuzzi, F.; Frantellizzi, V.; Piccardo, A.; et al. The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors. Curr. Oncol. 2021, 28, 2481–2495. [Google Scholar] [CrossRef] [PubMed]
  10. Laudicella, R.; Quartuccio, N.; Argiroffi, G.; Alongi, P.; Baratto, L.; Califaretti, E.; Frantellizzi, V.; De Vincentis, G.; Del Sole, A.; Evangelista, L.; et al. Unconventional Non-Amino Acidic PET Radiotracers for Molecular Imaging in Gliomas. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 3925–3939. [Google Scholar] [CrossRef] [PubMed]
  11. Russo, G.; Stefano, A.; Alongi, P.; Comelli, A.; Catalfamo, B.; Mantarro, C.; Longo, C.; Altieri, R.; Certo, F.; Cosentino, S.; et al. Feasibility on the Use of Radiomics Features of 11 [C]-MET PET/CT in Central Nervous System Tumours: Preliminary Results on Potential Grading Discrimination Using a Machine Learning Model. Curr. Oncol. 2021, 28, 5318–5331. [Google Scholar] [CrossRef] [PubMed]
  12. Lohmann, P.; Elahmadawy, M.A.; Gutsche, R.; Werner, J.-M.; Bauer, E.K.; Ceccon, G.; Kocher, M.; Lerche, C.W.; Rapp, M.; Fink, G.R.; et al. FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. Cancers 2020, 12, 3835. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Alongi, P.; Vetrano, I.G. Advances in the In Vivo Quantitative and Qualitative Imaging Characterization of Gliomas. Cancers 2022, 14, 3324. https://doi.org/10.3390/cancers14143324

AMA Style

Alongi P, Vetrano IG. Advances in the In Vivo Quantitative and Qualitative Imaging Characterization of Gliomas. Cancers. 2022; 14(14):3324. https://doi.org/10.3390/cancers14143324

Chicago/Turabian Style

Alongi, Pierpaolo, and Ignazio Gaspare Vetrano. 2022. "Advances in the In Vivo Quantitative and Qualitative Imaging Characterization of Gliomas" Cancers 14, no. 14: 3324. https://doi.org/10.3390/cancers14143324

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop